Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial

Anne Boerekamps*, Anja De Weggheleire, Guido E. van den Berk, Fanny N. Lauw, Mark A. A. Claassen, Dirk Posthouwer, Wouter F. Bierman, Sebastiaan J. Hullegie, Stephanie Popping, David A. C. M. van de Vijver, Anthonius S. M. Dofferhoff, Gert Jan Kootstra, Eliane M. Leyten, Jan den Hollander, Marjo E. van Kasteren, Robert Soetekouw, Heidi S. M. Ammerlaan, Janke Schinkel, Eric Florence, Joop E. ArendsBart J. A. Rijnders

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

19 Citations (Web of Science)
Original languageEnglish
Pages (from-to)269-277
Number of pages9
JournalThe Lancet Gastroenterology and Hepatology
Volume4
Issue number4
DOIs
Publication statusPublished - Apr 2019

Keywords

  • HUMAN-IMMUNODEFICIENCY-VIRUS
  • HIV-INFECTED MEN
  • ACUTE HCV
  • SEX
  • SOFOSBUVIR
  • RIBAVIRIN
  • REINFECTION
  • COINFECTION
  • COMBINATION
  • INTERFERON

Cite this